Dr. Peter Rossing Chief Physician, Steno Diabetes Center, Gentofte, Denmark

Peter Rossing has investigated key features of the pathophysiology of the diabetic kidney at different stages, in epidemiological studies. He has identified several markers for development of diabetic nephropathy, making it possible to predict the individual risk. He demonstrated that a reduction in urinary albumin excretion after onset of antihypertensive therapy in diabetic nephropathy was the best predictor of a successful treatment outcome. He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis. In addition to studies on conventional antihypertensive agents, he has been involved in some of the first studies of angiotensin II receptor blockers, aldosterone antagonists and most recently studies of direct renin inhibition with Aliskiren in diabetic kidney disease.